

Instructions For Use

RA0031-C.5-IFU-RUO

Rev. Date: Sept. 26, 2014

Revision: 1

Page 1 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

CD1a / HTA1 (Mature Langerhans Cells Marker); Clone O10 (Concentrate)

Availability/Contents: Item # Volume
RA0031-C.5 Volume
0.5 ml

Description:

Species: Mouse

Immunogen: Human thymus cells

Clone: O10

Isotype: IgG1, kappa Entrez Gene ID: 909 (Human) Hu Chromosome Loc.: 1q23.1

Synonyms: Cortical thymocyte antigen CD1A, Epidermal dendritic cell marker CD1a, FCB6, HTA1, T-cell

surface antigen T6 / Leu 6, T-Cell Surface Glycoprotein CD1A

Mol. Weight of Antigen: 49kDa

Format: 200µg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS

with 0.05% BSA & 0.05% azide.

Specificity: Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma,

a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of

the lymph node.

Background: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been

demonstrated to restrict T-cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class I related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for

perivascular epithelial cell tumor (PEComa).

Species Reactivity: Human. Others not known.

Positive Control: MOLT-4 cells. Paracortex in a tonsil or a reactive lymph node.

Cellular Localization: Cell surface

Titer/ Working Dilution: Immunohistochemistry (Frozen and Formalin-fixed): 0.5 -1 µg/ml

Flow Cytometry: 0.5-1 µg/million cells

Immunofluorescence: 1-2μg/ml
Western Blotting: 0.5-1 μg/ml

Immunoprecipitation: 1-2 μg/500μg protein lysate

Microbiological State: This product is not sterile.

Storage: 2° C 8° C

ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.

CE

EmergoEurope (31)(0) 70 345-8570 Molsnstraat 15 2513 BH Hague, The Netherlands



Instructions For Use RA0031-C.5-IFU-RUO

Rev. Date: Sept. 26, 2014

Revision: 1

Page 2 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

Uses/Limitations: Not to be taken internally.

For Research Use Only.

This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded


tissue sections, to be viewed by light

microscopy.

Do not use if reagent becomes cloudy. Do not use past expiration date.

Non-Sterile.

Ordering Information and Current Pricing at www.scytek.com



Formalin-fixed paraffin-embedded human skin tissue (40X) stained with CD1a; Clone O10.

- Tissue Section Pretreatment (Required): Staining of formalin fixed, paraffin embedded tissue sections is significantly enhanced by pretreatment with Citrate Plus (ScyTek catalog# CPL500).
- Primary Antibody Incubation Time: We suggest an incubation period of 30 minutes at room temperature.
 However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
- 3. **Visualization:** For maximum staining intensity we recommend the "UltraTek HRP Anti-Polyvalent Lab Pack" (ScyTek catalog# UHP125, see IFU for instructions) combined with the "DAB Chromogen/Substrate Bulk Pack (High Contrast)" (ScyTek catalog# ACV500, see IFU for instructions).

Precautions:

Procedure:

Contains Sodium Azide as a preservative (0.09% w/v).

Do not pipette by mouth.

Avoid contact of reagents and specimens with skin and mucous membranes.

Avoid microbial contamination of reagents or increased nonspecific staining may occur.

This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200,

OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

References:

- 1. McNally, AK. et al. 2011. Exp. Mol. Pathol. 91: 673-681.
- 2. Matsuda, A. et al. 2009. Invest. Ophthalmol. Vis. Sci. 50: 2871-2877.
- 3. Gulubova, M. et al. 2008. Clin. Exp. Metastasis. 25: 777-785.
- 4. Cassaday, RD. et al. 2007. Clin. Cancer Res. 13: 540-549.

Warranty:

No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.

Storage: 2° C

ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.

CE

EC REP EmergoEurope (31)(0) 70 345-8570 Molsnstraat 15 2513 BH Hague, The Netherlands